S&P gives AA to Pfizer notes

S&P said it assigned its AA senior unsecured debt rating to Pfizer Inc.'s announced senior unsecured multi-tranche debt offering, with maturities between 2021-2048.

“We deem that the transaction does not materially affect Pfizer's long-term net leverage,” S&P said in a news release.

“Our AA long-term issuer credit rating on New York City-based pharmaceutical giant Pfizer reflects the company's diverse portfolio of high-margin pharmaceuticals, with particular strengths in neurology, oncology, and vaccines.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.